Spore-like Cell Subpopulations for Regenerative Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for using pluripotent cells in regenerative therapy face challenges in controlling the growth and differentiation of cells into specific types for treating injuries and diseases, and there is a need for new approaches to generate transplantable multi- and pluripotent cells, as well as limited sources for these cells.
Innovation Solution
Identification and isolation of subpopulations of spore-like cells expressing specific cell surface or gene expression markers, such as Oct4, nanog, and others, which can be induced to differentiate into cells of endodermal, mesodermal, or ectodermal origin, and methods for purifying these cells using antibodies and marker-based selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If pluripotent cells are used for regenerative therapy, then the ability to differentiate into multiple cell types is improved, but the control over growth and differentiation into specific cell types deteriorates
Solution Approach 1:
The patent segments the pluripotent cell population into distinct subpopulations based on cell surface markers (CD34+, CD90+, cKit+ combinations). This segmentation allows each subpopulation to have more predictable differentiation potential while maintaining the overall versatility of the system. The markers divide the complex pluripotent cell群体 into manageable groups with specific therapeutic applications.
Solution Approach 2:
The patent applies local quality by assigning different marker profiles to different functional subpopulations. Each subpopulation (defined by specific combinations of CD34, CD90, and cKit markers) has distinct differentiation characteristics and therapeutic applications. This allows targeted selection of cell subpopulations for specific tissue regeneration needs rather than using homogeneous pluripotent cells.
2Reliability
If stem cells are isolated from non-embryonic tissues, then ethical considerations are improved, but the source availability and cell quantity deteriorates
Solution Approach 1:
The patent extracts and isolates specific stem cell subpopulations from non-embryonic tissues (bone marrow, adipose tissue, peripheral blood) using marker-based selection. By taking out the desired CD34+, CD90+, cKit+ subpopulations from these adult tissue sources, the invention achieves ethical acceptability while obtaining sufficient cell quantities for therapeutic applications without relying on embryonic sources.
Solution Approach 2:
The patent changes the selection parameters from traditional morphological or functional assays to specific cell surface marker expression profiles (CD34, CD90, cKit). This parameter change enables more efficient isolation and expansion of stem cells from non-embryonic sources, increasing the available cell quantity while maintaining ethical standards.
3Reliability
If spore-like cells are used for transplantation, then the tolerance for oxygen deprivation is improved, but the precision in generating specific cell types deteriorates
Solution Approach 1:
The patent segments the spore-like cell population into marker-defined subpopulations (CD34+, CD90+, cKit+ combinations) before transplantation. This segmentation preserves the hardy, oxygen-deprived nature of spore-like cells while adding precision through marker selection. Each subpopulation maintains survival tolerance while having more predictable differentiation potential for specific cell types.
Solution Approach 2:
The patent performs preliminary marker-based selection and characterization of spore-like cell subpopulations before transplantation. By pre-sorting cells based on CD34, CD90, and cKit expression, the invention ensures both the survival advantages of spore-like cells and the precision needed for generating specific cell types in the target tissue.
Data Source
AI summary
Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.